Mesalazine

Generic Name
Mesalazine
Brand Names
Apriso, Asacol, Canasa, Delzicol, Lialda, Mezavant, Pentasa, Rowasa, Salofalk, Zaldyon
Drug Type
Small Molecule
Chemical Formula
C7H7NO3
CAS Number
89-57-6
Unique Ingredient Identifier
4Q81I59GXC
Background

An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease . Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stabil...

Indication

适用于溃疡性结肠炎和克罗恩病（Crohn病）。

Associated Conditions
Acute Ulcerative Colitis, Crohn's Disease Relapse, Crohn's Ileocolitis, Mild to Moderate Ulcerative Colitis, Proctitis, Proctitis, Ulcerative, Proctosigmoiditis, Ulcerative Colitis in Remission, Mild Ulcerative Colitis, Mild to moderate distal ulcerative colitis, Moderate Ulcerative colitis
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Delzicol
Drug: IBD98-M without HA
First Posted Date
2014-07-22
Last Posted Date
2015-04-22
Lead Sponsor
Holy Stone Healthcare Co., Ltd
Target Recruit Count
30
Registration Number
NCT02196662
Locations
🇨🇦

inVentiv Health Clinique, Quebec, Canada

Taste Assessment Study of SHP429 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Mesalamine
First Posted Date
2014-04-29
Last Posted Date
2021-06-03
Lead Sponsor
Shire
Target Recruit Count
18
Registration Number
NCT02125292
Locations
🇺🇸

Clinical Pharmacology of Miami, Inc., Miami, Florida, United States

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Drug: Mesalazine
First Posted Date
2014-03-04
Last Posted Date
2016-12-02
Lead Sponsor
SOFAR S.p.A.
Target Recruit Count
21
Registration Number
NCT02077777
Locations
🇮🇹

Istituti Ospitalieri di Cremona, Cremona, Italy

Mesalazine Effects in Sporadic Colorectal Adenoma Patients

Phase 2
Completed
Conditions
Sporadic Colorectal Adenoma
Interventions
Drug: Mesalazine
Drug: Placebo
First Posted Date
2013-07-10
Last Posted Date
2015-12-08
Lead Sponsor
UMC Utrecht
Target Recruit Count
74
Registration Number
NCT01894685
Locations
🇳🇱

University Medical Center Utrecht, Utrecht, Netherlands

Mesalamine in Environmental Enteropathy

Phase 1
Completed
Conditions
Malnutrition
Interventions
Drug: Placebo granules
Drug: Mesalamine
First Posted Date
2013-04-26
Last Posted Date
2014-07-11
Lead Sponsor
Kelsey Jones
Target Recruit Count
44
Registration Number
NCT01841099
Locations
🇰🇪

Baraka Clinic, Nairobi, Mathare, Kenya

Evaluation of the Metabolome in Diverticular Disease

First Posted Date
2013-04-15
Last Posted Date
2014-10-17
Lead Sponsor
S.Eugenio Hospital
Target Recruit Count
40
Registration Number
NCT01831323
Locations
🇮🇹

Sant'Eugenio Hospital, Rome, RM, Italy

Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia

First Posted Date
2013-02-12
Last Posted Date
2013-02-12
Lead Sponsor
Azienda Policlinico Umberto I
Target Recruit Count
270
Registration Number
NCT01789294
Locations
🇮🇹

Departments of Pediatrics, Sapienza - University of Rome, Rome, Italy

Mesalazine Treatment in IBS (The MIBS Study)

Phase 2
Completed
Conditions
Irritable Bowel Syndrome
Interventions
Drug: Placebo
Drug: Mesalazine
First Posted Date
2012-10-03
Last Posted Date
2017-02-24
Lead Sponsor
Hans Törnblom
Target Recruit Count
211
Registration Number
NCT01699438
Locations
🇸🇪

Sahlgrenska University Hospital, Göteborg, Sweden

🇸🇪

Norrland's University Hospital, Umeå, Sweden

🇸🇪

Karolinska University Hospital, Huddinge, Sweden

Cimzia Versus Mesalamine for Crohn's Recurrence

Phase 4
Terminated
Conditions
Crohn's Disease
Interventions
Drug: Cimzia
Drug: Mesalamine
First Posted Date
2012-10-02
Last Posted Date
2018-01-12
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
10
Registration Number
NCT01696942
Locations
🇺🇸

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study

Phase 2
Completed
Conditions
Colonic Diverticulosis
Interventions
Drug: Placebo
Drug: Mesalamine
First Posted Date
2012-06-25
Last Posted Date
2016-01-21
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
123
Registration Number
NCT01627262
Locations
🇩🇪

Ev. Krankenhaus Kalk, University of Cologne, Köln, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy